Kintsugi CEO Grace Chang is hopeful that the company’s voice biomarkers technology for detecting depression and anxiety from short clips of free speech will receive the nod of approval from US regulators. (Also see "CES 2022: Defying Omicron, World’s Biggest Tech Show Goes Live In Las Vegas" - Medtech Insight, 6 January, 2022.)
The software has been already integrated for further evaluation in call centers, telehealth services and remote monitoring apps to screen and triage patients who are reaching out for support
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?